Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon13.,
Disease:Adenocarcinoma
Product details:
Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-EEA1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EEA1 (Early Endosome Antigen 1) is an important protein involved in endosomal trafficking with a molecular weight of approximately 162 kDa. It is a cytoplasmic protein expressed in various cell types acting mainly as an endosome marker. This protein contains a FYVE domain which facilitates binding to phosphatidylinositol 3-phosphate on endosomal membranes. EEA1 also interacts with Rab5 a small GTPase contributing to the fusion of early endosomes.
Biological function summary
EEA1 plays a significant role in early endosomal pathways facilitating endocytic vesicle fusion. EEA1 does not usually work alone; it functions as part of a larger complex involving other endosomal proteins. This protein acts as a tethering molecule which stabilizes the interaction of vesicles with endosomes. By anchoring vesicles EEA1 ensures the correct delivery and sorting of cargo within the cell which is important for cellular homeostasis and signaling.
Pathways
EEA1 contributes to the endocytic pathway and receptor recycling. It ensures proper functioning of the endocytic recycling of receptors such as the epidermal growth factor receptor (EGFR). EEA1-mediated tethering is vital for these pathways and it works closely with proteins like Rab5 which regulate endocytic trafficking. Through these interactions EEA1 affects cellular processes by controlling the flow of signaling receptors and other molecules within the cell.
EEA1 dysfunction is linked to neurodegenerative diseases and cancer. Abnormalities in its expression or function can disrupt endosomal trafficking leading to cellular stress and disease. For example in Alzheimer's disease impaired endosomal function involving EEA1 can contribute to amyloid-beta accumulation. In cancer altered EEA1 activity may contribute to aberrant receptor signaling which can promote unchecked cell division. The interplay with proteins like EGFR demonstrates EEA1's importance in maintaining cellular health and response mechanisms.
